Search - tctmd.com

Displaying 221 - 240 of 370

Sort: Relevancy | Date

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

Podcast Heart Sounds

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Michael O'Riordan

April 15, 2019

News Daily News

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Michael O'Riordan

April 11, 2019

News Daily News

Race, Socioeconomic Status Gaps in Revascularization Rates Persist Among Women With ACS

Yael L. Maxwell

April 05, 2019

News Opinion Fellow Talk

Public Reporting and the Budding Interventional Cardiologist

Yashasvi Chugh, MD

March 28, 2019

Time and Money: PCI Public Reporting Requirements Takes Their Toll

News Conference News ACC 2019

Time and Money: PCI Public Reporting Requirements Take Their Toll

Michael O'Riordan

March 26, 2019

News Daily News

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

Michael O'Riordan

March 19, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Advertisement

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Top Stories in Cardiology: April 2019

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Race, Socioeconomic Status Gaps in Revascularization Rates Persist Among Women With ACS

Public Reporting and the Budding Interventional Cardiologist

Time and Money: PCI Public Reporting Requirements Take Their Toll

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content